MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorREIS, Sabrina Thalita
dc.contributor.authorPONTES-JUNIOR, Jose
dc.contributor.authorANTUNES, Alberto Azoubel
dc.contributor.authorSOUSA-CANAVEZ, Juliana Moreira de
dc.contributor.authorDALL'OGLIO, Marcos Francisco
dc.contributor.authorPASSEROTTI, Carlo C.
dc.contributor.authorABE, Daniel Kanda
dc.contributor.authorCRIPPA, Alexandre
dc.contributor.authorCRUZ, Jose Arnaldo Shiomi da
dc.contributor.authorTIMOSZCZUK, Luciana M. S.
dc.contributor.authorSROUGI, Miguel
dc.contributor.authorLEITE, Katia R. M.
dc.date.accessioned2017-11-27T16:20:35Z
dc.date.available2017-11-27T16:20:35Z
dc.date.issued2011
dc.description.abstractBackground: Extracellular matrix homeostasis is strictly maintained by a coordinated balance between the expression of metalloproteinases (MMPs) and their inhibitors. The purpose of this study was to investigate whether the expression of MMP-9 and its specific inhibitors, TIMP-1 and RECK, are expressed in a reproducible, specific pattern and if the profiles are related to prognosis and clinical outcome in prostate cancer (PC). Methods: MMP-9, TIMP-1, and RECK expression levels were analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) in fresh-frozen malignant tissue specimens collected from 79 patients with clinically localized PC submitted to radical prostatectorny (RP). Frozen benign prostatic tissue from another 10 men with prostate cancer, also submitted to RP, was analyzed to determine if the profile of gene expression was maintained. The control group consisted of 11 patients with benign prostate hyperplasia (BPH). Results: In the tumor samples, MMP-9 was overexpressed by 9.2 times, and TIMP-1 and RECK were underexpressed (0.75 and 0.80 times, respectively). Overexpression of MMP-9 was significantly related to PSA levels above 10 ng/mL (p=0.033). In addition, MMP-9 overexpression was related to biochemical recurrence, with a marginal statistical significance (p=0.089). MMP-9 was also overexpressed in benign tissues of patients with PC, as were TIMP-1 and RECK, in contrast to their underexpression in tumor samples. Conclusion: Our results show that MMP-9 is overexpressed and its negative regulators are underexpressed in PC tissue, emphasizing a possible role of MMP-9 in the carcinogenesis process. Additionally, we noticed a relationship between MMP-9 overexpression and increased levels of PSA, an important prognostic factor. In benign tissue adjacent to tumors, the MMP-9 equilibrium is likely maintained because the expression of its negative regulators is preserved.
dc.description.indexMEDLINE
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/50368-9]
dc.identifier.citationINTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, v.26, n.4, p.255-261, 2011
dc.identifier.doi10.5301/JBM.2011.8831
dc.identifier.issn0393-6155
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/22454
dc.language.isoeng
dc.publisherWICHTIG EDITORE
dc.relation.ispartofInternational Journal of Biological Markers
dc.rightsrestrictedAccess
dc.rights.holderCopyright WICHTIG EDITORE
dc.subjectDiagnosis
dc.subjectGene expression
dc.subjectMatrix metalloproteinase
dc.subjectPrognosis
dc.subjectProstate cancer
dc.subject.othermetastasis suppressor reck
dc.subject.othermatrix metalloproteinases
dc.subject.othermessenger-rna
dc.subject.otherprotein expression
dc.subject.othercolorectal-cancer
dc.subject.othertissue inhibitors
dc.subject.otheriv collagenases
dc.subject.otherdown-regulation
dc.subject.othertumor invasion
dc.subject.otherlung-cancer
dc.subject.wosBiotechnology & Applied Microbiology
dc.subject.wosOncology
dc.titleMMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.author.externalSOUSA-CANAVEZ, Juliana Moreira de:Genoa Biotechnol SA, Sao Paulo, Brazil
hcfmusp.citation.scopus26
hcfmusp.contributor.author-fmusphcSABRINA THALITA DOS REIS FARIA
hcfmusp.contributor.author-fmusphcJOSE PONTES JUNIOR
hcfmusp.contributor.author-fmusphcALBERTO AZOUBEL ANTUNES
hcfmusp.contributor.author-fmusphcMARCOS FRANCISCO DALL'OGLIO
hcfmusp.contributor.author-fmusphcCARLO CAMARGO PASSEROTTI
hcfmusp.contributor.author-fmusphcDANIEL KANDA ABE
hcfmusp.contributor.author-fmusphcALEXANDRE CRIPPA SANT ANNA
hcfmusp.contributor.author-fmusphcJOSE ARNALDO SHIOMI DA CRUZ
hcfmusp.contributor.author-fmusphcLUCIANA MARIA SEVO TIMOSZCZUK
hcfmusp.contributor.author-fmusphcMIGUEL SROUGI
hcfmusp.contributor.author-fmusphcKATIA RAMOS MOREIRA LEITE
hcfmusp.description.beginpage255
hcfmusp.description.endpage261
hcfmusp.description.issue4
hcfmusp.description.volume26
hcfmusp.origemWOS
hcfmusp.origem.pubmed22139647
hcfmusp.origem.scopus2-s2.0-84555203853
hcfmusp.origem.wosWOS:000302882700008
hcfmusp.publisher.cityMILAN
hcfmusp.publisher.countryITALY
hcfmusp.relation.referenceCox G, 2000, LUNG CANCER-J IASLC, V27, P81, DOI 10.1016/S0169-5002(99)00096-3
hcfmusp.relation.referenceSingh RD, 2011, INT J BIOL MARKER, V26, P27, DOI 10.5301/JBM.2011.6359
hcfmusp.relation.referenceCho NH, 2003, EUR UROL, V44, P560, DOI 10.1016/S0302-2838(03)00362-2
hcfmusp.relation.referenceKodate M, 1997, PATHOL INT, V47, P461, DOI 10.1111/j.1440-1827.1997.tb04525.x
hcfmusp.relation.referenceEissa S, 2007, EUR UROL, V52, P1388, DOI 10.1016/j.eururo.2007.04.006
hcfmusp.relation.referenceJemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.1002/caac.20073]
hcfmusp.relation.referencePYKE C, 1992, CANCER RES, V52, P1336
hcfmusp.relation.referenceToi M, 1998, BREAST CANCER RES TR, V52, P113, DOI 10.1023/A:1006167202856
hcfmusp.relation.referenceHenriet P, 1999, APMIS, V107, P111
hcfmusp.relation.referenceChang CK, 2008, J CELL MOL MED, V12, P2781, DOI 10.1111/j.1582-4934.2008.00215.x
hcfmusp.relation.referenceSimi L, 2004, LUNG CANCER-J IASLC, V45, P171, DOI 10.1016/j.lungcan.2004.01.014
hcfmusp.relation.referenceHsu MC, 2006, J BIOL CHEM, V281, P4718, DOI 10.1074/jbc.M510937200
hcfmusp.relation.referenceZhong WD, 2008, ONCOLOGY-BASEL, V75, P230, DOI 10.1159/000163852
hcfmusp.relation.referenceHeppner KJ, 1996, AM J PATHOL, V149, P273
hcfmusp.relation.referenceNawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.0.CO;2-P
hcfmusp.relation.referenceLiabakk NB, 1996, CANCER RES, V56, P190
hcfmusp.relation.referenceSasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552
hcfmusp.relation.referenceTakeuchi T, 2004, CLIN CANCER RES, V10, P5572, DOI 10.1158/1078-0432.CCR-03-0656
hcfmusp.relation.referencePolette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008
hcfmusp.relation.referenceLichtinghagen R, 2002, EUR UROL, V42, P398, DOI 10.1016/S0302-2838(02)00324-X
hcfmusp.relation.referenceTakahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221
hcfmusp.relation.referenceZerbib M, 2008, UROLOGY, V72, P25, DOI 10.1016/j.urology.2008.10.005
hcfmusp.relation.referenceNelson AR, 2000, J CLIN ONCOL, V18, P1135
hcfmusp.relation.referenceOh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9
hcfmusp.relation.referenceBerger AP, 2003, PROSTATE, V57, P93, DOI 10.1002/pros.10278
hcfmusp.relation.referenceChang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001
hcfmusp.relation.referenceChen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802, DOI 10.1016/0955-0674(92)90103-J
hcfmusp.relation.referenceFestuccia C, 2000, INT J CANCER, V85, P407, DOI 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8
hcfmusp.relation.referenceHAMDY FC, 1994, BRIT J CANCER, V69, P177, DOI 10.1038/bjc.1994.30
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication73be4bca-f8ad-443f-90b5-10e2e62b1e27
relation.isAuthorOfPublication8f302d44-7ff3-4af9-bb58-76bce498a3a6
relation.isAuthorOfPublication1e8c7153-c3dc-4c8f-8bf8-5e004f275e35
relation.isAuthorOfPublication0349f82a-1538-4caa-908f-f81634bd6256
relation.isAuthorOfPublication8a4777c3-953f-4ad5-af0b-8749d7ccbe39
relation.isAuthorOfPublicationa880b3b6-276f-41d5-bac4-910de6024fcc
relation.isAuthorOfPublication54c86cee-11db-447d-8efd-06f4d5ecf830
relation.isAuthorOfPublicationc7bbf619-489a-42a6-95ac-58d3195f95c9
relation.isAuthorOfPublicationb903d04e-1d75-4ea1-a0e1-0d0815775414
relation.isAuthorOfPublicationcff561dd-5732-4af5-abe9-538da0cdf4d2
relation.isAuthorOfPublication23772d3b-0da7-472f-8d56-e6312dbf95c1
relation.isAuthorOfPublication.latestForDiscovery73be4bca-f8ad-443f-90b5-10e2e62b1e27
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_REIS_MMP9_overexpression_due_to_TIMP1_and_RECK_underexpression_2011.PDF
Tamanho:
149.69 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/55